

Elisabet Svenungsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8806705/publications.pdf>

Version: 2024-02-01

188
papers

9,191
citations

61857

43
h-index

45213

90
g-index

190
all docs

190
docs citations

190
times ranked

8846
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2023, 75, 998-1006.	1.5	7
2	Four Systemic Lupus Erythematosus Subgroups, Defined by Autoantibodies Status, Differ Regarding <i>HLA-DRB1</i> Genotype Associations and Immunological and Clinical Manifestations. <i>ACR Open Rheumatology</i> , 2022, 4, 27-39.	0.9	25
3	Antiphospholipid antibodies in patients with myocardial infarction with and without obstructive coronary arteries. <i>Journal of Internal Medicine</i> , 2022, 291, 327-337.	2.7	3
4	Gestational Diabetes Mellitus Risk in Pregnant Women With Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2022, 49, 465-469.	1.0	9
5	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 768-779.	0.5	128
6	Antibodies to <i>Porphyromonas gingivalis</i> Are Increased in Patients with Severe Periodontitis, and Associate with Presence of Specific Autoantibodies and Myocardial Infarction. <i>Journal of Clinical Medicine</i> , 2022, 11, 1008.	1.0	2
7	Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2022, 9, e000607.	1.1	7
8	Complement <i>C4</i> Copy Number Variation is Linked to SSA/Ro and SSB/La Autoantibodies in Systemic Inflammatory Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2022, 74, 1440-1450.	2.9	17
9	Maternal Hypertensive Disorders in Pregnant Women With Systemic Lupus Erythematosus and Future Cardiovascular Outcomes. <i>Arthritis Care and Research</i> , 2021, 73, 574-579.	1.5	7
10	Contributions of de novo variants to systemic lupus erythematosus. <i>European Journal of Human Genetics</i> , 2021, 29, 184-193.	1.4	6
11	Toll-like receptors revisited; a possible role for TLR1 in lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 404-406.	0.5	7
12	Interferon activation status underlies higher antibody response to viral antigens in patients with systemic lupus erythematosus receiving no or light treatment. <i>Rheumatology</i> , 2021, 60, 1445-1455.	0.9	4
13	Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 109-117.	0.5	35
14	The Complex Relationship between C4b-Binding Protein, Warfarin, and Antiphospholipid Antibodies. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1299-1309.	1.8	3
15	Interaction between the <i>STAT4</i> rs11889341(T) risk allele and smoking confers increased risk of myocardial infarction and nephritis in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1183-1189.	0.5	10
16	Activated low-density granulocytes in peripheral and intervillous blood and neutrophil inflammation in placentas from SLE pregnancies. <i>Lupus Science and Medicine</i> , 2021, 8, e000463.	1.1	8
17	Proteome study of cutaneous lupus erythematosus (CLE) and dermatomyositis skin lesions reveals IL-16 is differentially upregulated in CLE. <i>Arthritis Research and Therapy</i> , 2021, 23, 132.	1.6	12
18	Associations with thrombosis are stronger for antiphosphatidylserine/prothrombin antibodies than for the Sydney criteria antiphospholipid antibody tests in SLE. <i>Lupus</i> , 2021, 30, 1289-1299.	0.8	6

#	ARTICLE	IF	CITATIONS
19	AB0318â€¦RISK FOR CONCOMITANT AUTOIMMUNITY IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME; A SWEDISH COHORT STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1184.1-1184.	0.5	0
20	Quick Systemic Lupus Activity Questionnaire (Q-SLAQ): a simplified version of SLAQ for patient-reported disease activity. <i>Lupus Science and Medicine</i> , 2021, 8, e000471.	1.1	4
21	POS0764â€¦EULAR RECOMMENDATION-BASED QUALITY INDICATORS (QIS) FOR SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): ELABORATION, FINAL SET, PERFORMANCE AND INITIAL VALIDATION. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 635.2-636.	0.5	0
22	POS0184â€¦URINE-GALECTINE 3 BINDING PROTEIN (U-GAL3BP) IS A SENSITIVE MARKER OF KIDNEY INFLAMMATION AND RESPONSE TO TREATMENT IN LUPUS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 305.2-306.	0.5	0
23	POS1425â€¦ANTIBODIES TO PORPHYROMONAS GINGIVALIS ASSOCIATE WITH THE PRESENCE OF RHEUMATOID ARTHRITIS-RELATED AUTOANTIBODIES IN PATIENTS WITH PERIODONTITIS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 996.1-996.	0.5	1
24	A Comprehensive Evaluation of the Relationship Between Different IgG and IgA Anti-Modified Protein Autoantibodies in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2021, 12, 627986.	2.2	23
25	POS0009â€¦THE RELATIONSHIP BETWEEN DIFFERENT IGG AND IGA ANTI-MODIFIED PROTEIN AUTOANTIBODIES IN RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 206.1-207.	0.5	0
26	Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1175-1182.	0.5	9
27	Variants in BANK1 are associated with lupus nephritis of European ancestry. <i>Genes and Immunity</i> , 2021, 22, 194-202.	2.2	9
28	Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a caseâ€“control study. <i>Lupus Science and Medicine</i> , 2021, 8, e000515.	1.1	7
29	DNA Methylation-Based Interferon Scores Associate With Sub-Phenotypes in Primary Sjögrenâ€™s Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 702037.	2.2	13
30	Global epidemiology of systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2021, 17, 515-532.	3.5	229
31	Infection hospitalisation in systemic lupus in Sweden. <i>Lupus Science and Medicine</i> , 2021, 8, e000510.	1.1	11
32	Factors Associated With Self-Reported Capacity to Walk, Jog and Run in Individuals With Systemic Lupus Erythematosus. <i>Archives of Rheumatology</i> , 2021, 36, 89-100.	0.3	0
33	Long term outcome after a first myocardial infarction. <i>European Heart Journal</i> , 2021, 42, .	1.0	0
34	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. <i>Lupus Science and Medicine</i> , 2021, 8, e000590.	1.1	31
35	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 67-77.	2.9	39
36	Sudanese and Swedish patients with systemic lupus erythematosus: immunological and clinical comparisons. <i>Rheumatology</i> , 2020, 59, 968-978.	0.9	15

#	ARTICLE	IF	CITATIONS
37	NCF1-339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 254-261.	0.5	30
38	Epilepsy in systemic lupus erythematosus: prevalence and risk factors. <i>European Journal of Neurology</i> , 2020, 27, 297-307.	1.7	16
39	ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus. <i>Rheumatology</i> , 2020, 59, 2237-2249.	0.9	34
40	High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 363-369.	0.5	76
41	P37...Non-invasive biomarkers of disease activity in systemic lupus erythematosus. , 2020, , .		0
42	P86...The NCF1...339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus. , 2020, , .		1
43	P89...Epigenome-wide association study reveals differential DNA methylation in systemic lupus erythematosus patients with a history of ischemic heart disease. , 2020, , .		0
44	O30...Complement deposition, C4d, on platelets is associated with vascular events and antiphospholipid antibodies in systemic lupus erythematosus. , 2020, , .		0
45	High IgA antiphospholipid autoantibodies in healthy Sudanese explain the increased prevalence among Sudanese compared to Swedish systemic lupus erythematosus patients. <i>Lupus</i> , 2020, 29, 1412-1422.	0.8	4
46	Accumulation of antinuclear associated antibodies in circulating immune complexes is more prominent in SLE patients from Sudan than Sweden. <i>Scientific Reports</i> , 2020, 10, 21126.	1.6	4
47	O32...Skin proteome investigation in cutaneous lupus erythematosus (CLE) reveals novel unique disease pathways. , 2020, , .		0
48	Could severe COVID-19 be considered a complementopathy?. <i>Lupus Science and Medicine</i> , 2020, 7, e000415.	1.1	6
49	Antiphospholipid antibodies in patients with dysglycaemia: A neglected cardiovascular risk factor?. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412092212.	0.9	1
50	Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1387-1393.	1.6	16
51	Elevated IgA antiphospholipid antibodies in healthy pregnant women in Sudan but not Sweden, without corresponding increase in IgA anti-Î² ₂ glycoprotein I domain 1 antibodies. <i>Lupus</i> , 2020, 29, 463-473.	0.8	6
52	The binding of SLE autoantibodies to mitochondria. <i>Clinical Immunology</i> , 2020, 212, 108349.	1.4	16
53	The antiphospholipid syndrome " often overlooked cause of vascular occlusions?. <i>Journal of Internal Medicine</i> , 2020, 287, 349-372.	2.7	27
54	Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus. <i>Rheumatology</i> , 2020, 59, 3264-3274.	0.9	22

#	ARTICLE	IF	CITATIONS
55	Sjögren Syndrome in Systemic Lupus Erythematosus: A Subset Characterized by a Systemic Inflammatory State. <i>Journal of Rheumatology</i> , 2020, 47, 865-875.	1.0	28
56	Response to Comment on Norhammar et al. Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study. <i>Diabetes Care</i> 2019;42:1504-1511. <i>Diabetes Care</i> , 2020, 43, e9-e9.	4.3	0
57	OP0101-HPR...QUALITY OF LIFE IN PEOPLE WITH SYSTEMIC SCLEROSIS WITH DIFFERENT DEGREES OF LUNG DISEASE - A CROSS-SECTIONAL STUDY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 66.3-66.	0.5	0
58	AB0127...ACCUMULATION OF ANTI-NUCLEAR ASSOCIATED AUTOANTIBODIES IN CIRCULATING IMMUNE COMPLEXES IS MORE PROMINENT IN SLE PATIENTS FROM SUDAN COMPARED TO SWEDEN. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1364-1365.	0.5	0
59	THU0224...SKIN PROTEOME INVESTIGATION IN CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) REVEALS NOVEL UNIQUE DISEASE PATHWAYS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 339.2-339.	0.5	0
60	SAT0204...COMPARING OCCURRENCE AND CLINICAL SIGNIFICANCE OF ANTI-PHOSPHOLIPID AUTOANTIBODIES AMONG SUDANESE AND SWEDISH SLE PATIENTS USING CONVENTIONAL AND NATION-BASED CUTOFFS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1044.2-1045.	0.5	0
61	Muscle endurance, strength, and active range of motion in patients with different subphenotypes in systemic sclerosis: a cross-sectional cohort study. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 141-148.	0.6	14
62	Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 16955-16960.	3.3	120
63	Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1363-1370.	0.5	60
64	Do DMARDs and biologic agents protect from cardiovascular disease in patients with inflammatory arthropathies?. <i>Autoimmunity Reviews</i> , 2019, 18, 102401.	2.5	7
65	Whole-genome sequencing identifies complex contributions to genetic risk by variants in genes causing monogenic systemic lupus erythematosus. <i>Human Genetics</i> , 2019, 138, 141-150.	1.8	63
66	Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study. <i>Diabetes Care</i> , 2019, 42, 1504-1511.	4.3	16
67	Circulating Levels of Interferon Regulatory Factor-5 Associates With Subgroups of Systemic Lupus Erythematosus Patients. <i>Frontiers in Immunology</i> , 2019, 10, 1029.	2.2	11
68	Microparticles in the blood of patients with SLE: Size, content of mitochondria and role in circulating immune complexes. <i>Journal of Autoimmunity</i> , 2019, 102, 142-149.	3.0	38
69	High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2019, 21, 107.	1.6	129
70	EULAR recommendations for the management of antiphospholipid syndrome in adults. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1296-1304.	0.5	664
71	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 736-745.	0.5	1,265
72	Mass spectrometry-based analysis of cerebrospinal fluid from arthritis patients' immune-related candidate proteins affected by TNF blocking treatment. <i>Arthritis Research and Therapy</i> , 2019, 21, 60.	1.6	10

#	ARTICLE	IF	CITATIONS
73	Cytokine Profiles in Autoantibody Defined Subgroups of Systemic Lupus Erythematosus. Journal of Proteome Research, 2019, 18, 1208-1217.	1.8	17
74	Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren's syndrome differ in molecular signatures and treatment perspectives. Arthritis Research and Therapy, 2019, 21, 62.	1.6	24
75	FRIO193...2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		6
76	FRIO192...A SYSTEMATIC LITERATURE REVIEW TO INFORM THE 2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
77	AB1401-HPR...SELF-REPORTED PHYSICAL FUNCTION AND ASSOCIATED FACTORS IN INDIVIDUALS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
78	Sex differences in clinical presentation of systemic lupus erythematosus. Biology of Sex Differences, 2019, 10, 60.	1.8	55
79	A rare regulatory variant in the MEF2D gene affects gene regulation and splicing and is associated with a SLE sub-phenotype in Swedish cohorts. European Journal of Human Genetics, 2019, 27, 432-441.	1.4	12
80	Antiphospholipid Antibodies in Patients With Myocardial Infarction. Annals of Internal Medicine, 2019, 170, 277.	2.0	17
81	Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis. Annals of the Rheumatic Diseases, 2018, 77, 1063-1069.	0.5	41
82	Cardiovascular disease in systemic lupus erythematosus is associated with increased levels of biomarkers reflecting receptor-activated apoptosis. Atherosclerosis, 2018, 270, 1-7.	0.4	27
83	DNA methylation mapping identifies gene regulatory effects in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2018, 77, 736-743.	0.5	135
84	Response to: "Increased stroke incidence in systemic lupus erythematosus patients: risk factors or disease itself?" by Bruzzese and Zullo. Annals of the Rheumatic Diseases, 2018, 77, e72-e72.	0.5	0
85	PS4:71...Iga anti-phospholipid antibodies in swedish cases with systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual. , 2018, , .		0
86	S4D:5...Targeted next-generation sequencing suggests novel risk loci in juvenile onset systemic lupus erythematosus. , 2018, , .		2
87	Obstetric antiphospholipid syndrome. Lupus Science and Medicine, 2018, 5, e000197.	1.1	42
88	Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual. Clinical and Experimental Immunology, 2018, 194, 27-38.	1.1	16
89	Kynurenine pathway is altered in patients with SLE and associated with severe fatigue. Lupus Science and Medicine, 2018, 5, e000254.	1.1	51
90	Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus " distinct roles of BAFF and APRIL. Lupus, 2018, 27, 1470-1478.	0.8	24

#	ARTICLE	IF	CITATIONS
91	Microparticles as autoantigens in systemic lupus erythematosus. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13010.	1.7	34
92	S4A:5â€...High genetic risk score is associated with organ damage in systemic lupus erythematosus. , 2018, , .		1
93	Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 36.	1.6	20
94	Dr. Rossides, et al reply. <i>Journal of Rheumatology</i> , 2018, 45, 1070.2-1070.	1.0	1
95	TNF-Î± and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2018, 5, e000260.	1.1	73
96	OPO362â€...Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis. , 2018, , .		1
97	EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 476-485.	0.5	590
98	Effect of Corticosteroids and Cyclophosphamide on Sex Hormone Profiles in Male Patients With Systemic Lupus Erythematosus or Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1272-1279.	2.9	28
99	Stroke in systemic lupus erythematosus: a Swedish population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1544-1549.	0.5	86
100	05.01â€...Protein profiling in plasma reveals molecular subgroups in systemic lupus erythematosus. , 2017, , .		0
101	Dysregulations in circulating sphingolipids associate with disease activity indices in female patients with systemic lupus erythematosus: a cross-sectional study. <i>Lupus</i> , 2017, 26, 1023-1033.	0.8	36
102	A single nucleotide polymorphism in the <i>NCF1</i> gene leading to reduced oxidative burst is associated with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1607-1613.	0.5	103
103	Self-reported physical capacity and activity in patients with systemic sclerosis and matched controls. <i>Scandinavian Journal of Rheumatology</i> , 2017, 46, 490-495.	0.6	11
104	A comparison of patientsâ€™ and physiciansâ€™ assessments of disease activity using the Swedish version of the Systemic Lupus Activity Questionnaire. <i>Scandinavian Journal of Rheumatology</i> , 2017, 46, 474-483.	0.6	9
105	Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis. <i>Scandinavian Journal of Rheumatology</i> , 2017, 46, 263-272.	0.6	18
106	Earlyâ€onset Preeclampsia in Lupus Pregnancy. <i>Paediatric and Perinatal Epidemiology</i> , 2017, 31, 29-36.	0.8	36
107	Depressed serum IgM levels in SLE are restricted to defined subgroups. <i>Clinical Immunology</i> , 2017, 183, 304-315.	1.4	22
108	AB0159â€...Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
109	Multivariate strategy for the sample selection and integration of multi-batch data in metabolomics. <i>Metabolomics</i> , 2017, 13, 114.	1.4	12
110	Mortality and Functionality after Stroke in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2017, 44, 1590-1596.	1.0	11
111	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , 2017, 8, 16021.	5.8	314
112	Altered Î²2â€¦glycoproteinÎ expression on microparticles in the presence of antiphospholipid antibodies. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1799-1806.	1.9	17
113	Novel risk genes for systemic lupus erythematosus predicted by random forest classification. <i>Scientific Reports</i> , 2017, 7, 6236.	1.6	54
114	SAT0239â€¦Late-onset neutropenia following rituximab treatment in systemic lupus erythematosus â€œ a role of the baff/april pathway. , 2017, , .		0
115	IFN-Î³1 with Th17 axis cytokines and IFN-Î± define different subsets in systemic lupus erythematosus (SLE). <i>Arthritis Research and Therapy</i> , 2017, 19, 139.	1.6	54
116	Thrombin activatable fibrinolysis inhibitor (TAFI) â€œ A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS). <i>Thrombosis Research</i> , 2017, 158, 168-173.	0.8	14
117	Troponin I and echocardiography in patients with systemic sclerosis and matched population controls. <i>Scandinavian Journal of Rheumatology</i> , 2017, 46, 226-235.	0.6	19
118	380â€¦Comparisons of fatigue, anxiety and depression in systemic lupus erythematosus, systemic sclerosis and anti-neutrophil cytoplasmic antibody-associated vasculitis. , 2017, , .		0
119	237â€¦Ischaemic stroke in systemic lupus erythematosus, -distribution of subtypes and a risk genotype in the stat4 gene. , 2017, , .		0
120	Excess atherosclerosis in systemic lupus erythematosus,â€œA matter of renal involvement: Case control study of 281 SLE patients and 281 individually matched population controls. <i>PLoS ONE</i> , 2017, 12, e0174572.	1.1	88
121	OP0160â€¦Characterization of Systemic Lupus Erythematosus Subgroups with Features of Antiphospholipid or SjÃ¶gren's Syndrome Utilizing Affinity Proteomics. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 116.2-116.	0.5	0
122	Case definitions in Swedish register data to identify systemic lupus erythematosus. <i>BMJ Open</i> , 2016, 6, e007769.	0.8	39
123	Plateletâ€¦Derived S100A8/A9 and Cardiovascular Disease in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2016, 68, 1970-1980.	2.9	70
124	Interferon (IFN)-Î³ is a potential mediator in lupus nephritis. <i>Lupus Science and Medicine</i> , 2016, 3, e000170.	1.1	48
125	What to Expect When Expecting With Systemic Lupus Erythematosus (SLE): A Populationâ€¦Based Study of Maternal and Fetal Outcomes in SLE and Preâ€¦SLE. <i>Arthritis Care and Research</i> , 2016, 68, 988-994.	1.5	54
126	Ofatimumab treatment in lupus nephritis patients. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 552-555.	1.4	40

#	ARTICLE	IF	CITATIONS
127	Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations. <i>Scientific Reports</i> , 2016, 6, 36025.	1.6	83
128	OP0171â€¦Prognosis of Stroke Patients with Systemic Lupus Erythematosus: A Population-Based Cohort Study: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 120.2-120.	0.5	0
129	A6.15â€¦Characterisation of systemic lupus erythematosus subgroups with features of antiphospholipid or sjögrensÅ's syndrome utilising affinity proteomics. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, A53.2-A53.	0.5	0
130	Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 684-690.	1.6	23
131	Periodontitis Increases the Risk of a First Myocardial Infarction. <i>Circulation</i> , 2016, 133, 576-583.	1.6	200
132	Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2016, 15, 203-209.	2.5	50
133	Antiphospholipid Antibodies in Lupus Nephritis. <i>PLoS ONE</i> , 2016, 11, e0158076.	1.1	26
134	SAT0401â€¦Antiphospholipid Antibodies in Lupus Nephritis and Their Role in Long-Term Outcome. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 804.2-804.	0.5	0
135	Increased Serum Levels of the <scp>IL</scp>â€³3 Neutralizing <scp>sST</scp>2 in Limited Cutaneous Systemic Sclerosis. <i>Scandinavian Journal of Immunology</i> , 2015, 82, 269-274.	1.3	25
136	Lifestyle habits and fatigue among people with systemic lupus erythematosus and matched population controls. <i>Lupus</i> , 2015, 24, 955-965.	0.8	28
137	Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy. <i>Lupus Science and Medicine</i> , 2015, 2, e000061-e000061.	1.1	38
138	Prevention of cardiovascular disease in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2015, 14, 952-969.	2.5	69
139	Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus. <i>Clinical and Experimental Immunology</i> , 2015, 181, 417-426.	1.1	43
140	Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up. <i>Arthritis Research and Therapy</i> , 2015, 17, 109.	1.6	40
141	Cigarette smoking, antiphospholipid antibodies and vascular events in Systemic Lupus Erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1537-1543.	0.5	65
142	Systemic Lupus Erythematosus Prevalence in Sweden in 2010: What Do National Registers Say?. <i>Arthritis Care and Research</i> , 2014, 66, 1710-1717.	1.5	26
143	Role of early repeated renal biopsies in lupus nephritis. <i>Lupus Science and Medicine</i> , 2014, 1, e000018.	1.1	96
144	Studies of fibrin formation and fibrinolytic function in patients with the antiphospholipid syndrome. <i>Thrombosis Research</i> , 2014, 133, 936-944.	0.8	23

#	ARTICLE	IF	CITATIONS
145	Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus. Autoimmunity, 2014, 47, 67-76.	1.2	50
146	THU0530â€¦Blys and APRIL in Lupus Nephritis: Correlations with Serology - Blys as A Non-Invasive Predictor of Response. Annals of the Rheumatic Diseases, 2014, 73, 366.3-366.	0.5	0
147	FRI0172â€¦Utility of Swedish Register Data in Classifying Systemic Lupus. Annals of the Rheumatic Diseases, 2014, 73, 444.2-444.	0.5	0
148	AB0487â€¦Decreased SLE Disease Activity and Corticosteroid Usage and NO Renal Flares during Belimumab Treatment. Annals of the Rheumatic Diseases, 2014, 73, 968.2-968.	0.5	2
149	THU0520â€¦Interferon (IFN)-Lambda1/3, but not IFN-Alpha, is A Marker of Poor Response to Treatment in Lupus Nephritis. Annals of the Rheumatic Diseases, 2014, 73, 363.1-363.	0.5	0
150	Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. Rheumatology, 2013, 52, 501-509.	0.9	44
151	Coronary Heart Disease in Systemic Lupus Erythematosus Is Associated With Interferon Regulatory Factor-8 Gene Variants. Circulation: Cardiovascular Genetics, 2013, 6, 255-263.	5.1	40
152	HLA-DRB1*04/*13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2013, 72, 1018-1025.	0.5	49
153	AB0693â€¦Autoantibodies to the functionally active ring-domain of RO52/SSA associate with clinical activity in a subset of patients with lupus. Annals of the Rheumatic Diseases, 2013, 71, 678.7-678.	0.5	0
154	A10.23â€¦Stratification of SLE Patients for Improved Diagnosis and Treatment. Annals of the Rheumatic Diseases, 2013, 72, A80.2-A80.	0.5	0
155	FRI0271â€¦Stratification of sle patients for improved diagnosis and treatment. Annals of the Rheumatic Diseases, 2013, 72, A466.1-A466.	0.5	0
156	SAT0181â€¦Systems biology of SLE: Biochemical characterization of subgroups within SLE for improved diagnosis and treatment. Annals of the Rheumatic Diseases, 2013, 71, 532.3-532.	0.5	0
157	THU0162â€¦Thrombotic microangiopathy in renal biopsies from patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2013, 71, 210.2-210.	0.5	0
158	THU0309â€¦Coronary Heart Disease in Systemic Lupus Erythematosus is Associated with Interferon Regulatory Factor 8 Gene Variants. Annals of the Rheumatic Diseases, 2013, 72, A270.2-A270.	0.5	0
159	A Research Study of the Association between Maternal Microchimerism and Systemic Lupus Erythematosus in Adults: A Comparison between Patients and Healthy Controls Based on Single-Nucleotide Polymorphism Using Quantitative Real-Time PCR. PLoS ONE, 2013, 8, e74534.	1.1	11
160	Association of STAT4 Polymorphism with Severe Renal Insufficiency in Lupus Nephritis. PLoS ONE, 2013, 8, e84450.	1.1	88
161	Studies of microparticles in patients with the antiphospholipid syndrome (APS). Lupus, 2012, 21, 802-805.	0.8	46
162	Ischemic vascular disease and antiphospholipid antibodies are associated with HLA-DRB1 *04/*13 alleles in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2012, 71, A57.3-A58.	0.5	0

#	ARTICLE	IF	CITATIONS
163	Systems biology of SLE: biochemical characterisation of subgroups within sle for improved diagnosis and treatment. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A12.2-A12.	0.5	1
164	Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. <i>Arthritis Research and Therapy</i> , 2012, 14, R46.	1.6	127
165	Autoantibodies to the functionally active RING-domain of Ro52/SSA associate with clinical activity in a subset of patients with lupus. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A40.1-A40.	0.5	0
166	Cerebrospinal fluid levels of a proliferation-inducing ligand (APRIL) are increased in patients with neuropsychiatric systemic lupus erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 2011, 40, 363-372.	0.6	23
167	Low gene copy-number of complement C4A, the presence of HLA-DR3, and the presence of HLA-DR2 are independent and additive risk factors for human systemic lupus erythematosus. <i>Molecular Immunology</i> , 2010, 47, 2285-2285.	1.0	0
168	Genetic Risk Factors in Lupus Nephritis and IgA Nephropathy – No Support of an Overlap. <i>PLoS ONE</i> , 2010, 5, e10559.	1.1	24
169	A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 834-840.	0.5	68
170	Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study. <i>Arthritis Research and Therapy</i> , 2009, 11, R186.	1.6	129
171	Identification of MAMDC1 as a Candidate Susceptibility Gene for Systemic Lupus Erythematosus (SLE). <i>PLoS ONE</i> , 2009, 4, e8037.	1.1	14
172	Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 2008, 37, 352-359.	0.6	37
173	A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. <i>Human Molecular Genetics</i> , 2008, 17, 2868-2876.	1.4	183
174	Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. <i>Arthritis and Rheumatism</i> , 2005, 52, 192-200.	6.7	211
175	Decreased Binding of Annexin V to Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 198-203.	1.1	87
176	Title is missing!. <i>Arthritis Research</i> , 2005, 7, P105.	2.0	0
177	Endothelial function and activation in women with systemic lupus erythematosus. <i>Arthritis Research</i> , 2005, 7, P148.	2.0	0
178	Title is missing!. <i>Arthritis Research</i> , 2005, 7, P143.	2.0	0
179	Title is missing!. <i>Arthritis Research</i> , 2005, 7, P122.	2.0	0
180	Platelet-activating factor-acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004, 50, 2869-2876.	6.7	35

#	ARTICLE	IF	CITATIONS
181	The A-1087IL-10 allele is associated with cardiovascular disease in SLE. <i>Atherosclerosis</i> , 2004, 177, 409-414.	0.4	27
182	Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor α /tumor necrosis factor receptor system in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2003, 48, 2533-2540.	6.7	137
183	TNF- α : a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. <i>Lupus</i> , 2003, 12, 454-461.	0.8	131
184	Cardiac valvular abnormalities are frequent in systemic lupus erythematosus patients with manifest arterial disease. <i>Lupus</i> , 2002, 11, 744-752.	0.8	28
185	Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 372-379.	0.5	84
186	Risk Factors for Cardiovascular Disease in Systemic Lupus Erythematosus. <i>Circulation</i> , 2001, 104, 1887-1893.	1.6	450
187	Anticardiolipin Antibodies Predict Early Recurrence of Thromboembolism and Death Among Patients with Venous Thromboembolism Following Anticoagulant Therapy. <i>American Journal of Medicine</i> , 1998, 104, 332-338.	0.6	481
188	Anti-phosphatidylserine/prothrombin antibodies and thrombosis associate positively with HLA-DRB1*13 and negatively with HLA-DRB1*03 in SLE. <i>Rheumatology</i> , 0, , .	0.9	0